Discovery of Highly Potent Solute Carrier 13 Member 5 (SLC13A5) Inhibitors for the Treatment of Hyperlipidemia
Journal of Medicinal Chemistry · 25.04.2024 · 67 (8) · 6687-6704
DOI: 10.1021/acs.jmedchem.4c00260 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 04.04.2024. Verfasst von Li'ao Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, P. R. China. Hauptthemen laut MEDLINE: Hyperlipidemias. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: China Association for Science and Technology, Qinglan Project of Jiangsu Province of China, China Pharmaceutical University.
Abstract (Originalsprache)
In the face of escalating metabolic disease prevalence, largely driven by modern lifestyle factors, this study addresses the critical need for novel therapeutic approaches. We have identified the sodium-coupled citrate transporter (NaCT or SLC13A5) as a target for intervention. Utilizing rational drug design, we developed a new class of SLC13A5 inhibitors, anchored by the hydroxysuccinic acid scaffold, refining the structure of PF-06649298. Among these, LBA-3 emerged as a standout compound, exhibiting remarkable potency with an IC50 value of 67 nM, significantly improving upon PF-06649298. In vitro assays demonstrated LBA-3's efficacy in reducing triglyceride levels in OPA-induced HepG2 cells. Moreover, LBA-3 displayed superior pharmacokinetic properties and effectively lowered triglyceride and total cholesterol levels in diverse mouse models (PCN-stimulated and starvation-induced), without detectable toxicity. These findings not only spotlight LBA-3 as a promising candidate for hyperlipidemia treatment but also exemplify the potential of targeted molecular design in advancing metabolic disorder therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, P. R. China.
- Departments of Pharmacology, School of Pharmacy, China Pharmaceutical University, Nanjing 211100, P. R. China.
- Department of Pharmacology of Chinese Materia Medica, School of Traditional Chinese Pharmacy, Nanjing 211100, P. R. China.
ORCID-Profile: Xi Xu, Zhiyu Li, Zhixia Qiu, Jinlei Bian
Förderung
- China Association for Science and Technology
- Qinglan Project of Jiangsu Province of China
- China Pharmaceutical University
- China Scholarship Council
- National Natural Science Foundation of China
- Outstanding Youth Foundation of Jiangsu Province
- State Key Laboratory of Natural Medicines, China Pharmaceutical University
Zitieren
APA
Zhang, L., Hu, W., Guo, H., Sun, Q., Xu, X., Li, Z., Qiu, Z., & Bian, J. (2024). Discovery of Highly Potent Solute Carrier 13 Member 5 (SLC13A5) Inhibitors for the Treatment of Hyperlipidemia. Journal of Medicinal Chemistry, 67(8), 6687-6704. https://doi.org/10.1021/acs.jmedchem.4c00260
Vancouver
Zhang L, Hu W, Guo H, Sun Q, Xu X, Li Z, et al. Discovery of Highly Potent Solute Carrier 13 Member 5 (SLC13A5) Inhibitors for the Treatment of Hyperlipidemia. Journal of Medicinal Chemistry. 2024;67(8):6687-6704. doi:10.1021/acs.jmedchem.4c00260
BibTeX
@article{Zhang2024,
author = {Zhang, Li'ao and Hu, Wenjun and Guo, Huimin and Sun, Qiushuang and Xu, Xi and Li, Zhiyu and Qiu, Zhixia and Bian, Jinlei},
title = {Discovery of Highly Potent Solute Carrier 13 Member 5 (SLC13A5) Inhibitors for the Treatment of Hyperlipidemia},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {8},
pages = {6687--6704},
doi = {10.1021/acs.jmedchem.4c00260}
}
EUVIMED